FDA Approves Vivus’ Obesity Drug, Recommends Against Use In High-Risk Heart Patients
This article was originally published in The Pink Sheet Daily
Executive Summary
A Risk Evaluation and Mitigation Strategy for Qsymia includes prescriber education about the risk of birth defects and limits dispensing to specially certified pharmacies